IPO registrations (S-1, F-1) · Registrants
Absci Corp
- SEC CIK
- 1672688 · filings on EDGAR ↗
- Former names
- AbSci, LLC (2016–2019)
- Registration
- Form S-1, first filed 2021-06-30, last 2021-07-20; 1 initial registration, 4 amendments
- Outcome
- Final prospectus filed 2021-07-23; declared effective 2021-07-21
- Industry (SIC)
- Services-Commercial Physical & Biological Research 8731
- Business address
- 18105 SE MILL PLAIN BLVD, Vancouver, WA 98683
- EIN
- 85-3383487
- Ticker
- ABSI (Nasdaq)
- EDGAR entity type
- operating
- Insiders and CEO pay
- Absci Corp on the corporate pages
Offering terms
- Proposed price range
- $15.00–$17.00 per share (S-1/A filed 2021-07-20)
- Final price
- $16.00 per share, within the range (424B4 filed 2021-07-23, an initial public offering)
- Shares sold
- 12,500,000
- Gross proceeds
- $200,000,000 before underwriting discounts and any over-allotment option
- Listing
- Nasdaq under the symbol ABSI
- Lead underwriters
- J.P. Morgan
- Syndicate
- Credit Suisse; BofA Securities; Cowen; Stifel
Read from the cover pages of the filings listed under “Prospectus pages read” below; check the document for anything that matters.
On this site
- Business registration: ABSCI CORPORATION Fuzzy (name and state)
- Form 5500 plan sponsor: ABSCI CORPORATION EXACT (EIN (EXACT))
- Form D issuer: AbSci Corp EXACT (CIK (EXACT))
- Lobbying client: ABSCI Fuzzy (name and state)
- SEC filer: Absci Corp EXACT (CIK (EXACT))
Filings 8
| Filed | Form | What it is | Name as filed | EDGAR |
|---|---|---|---|---|
| 2021-06-30 | S-1 | S-1 (registration) | AbSci Corp | 0001628280-21-013214 ↗ |
| 2021-07-08 | S-1/A | S-1/A (amendment) | Absci Corp | 0001628280-21-013661 ↗ |
| 2021-07-15 | S-1/A | S-1/A (amendment) | Absci Corp | 0001628280-21-013857 ↗ |
| 2021-07-19 | S-1/A | S-1/A (amendment) | Absci Corp | 0001628280-21-014027 ↗ |
| 2021-07-20 | S-1/A | S-1/A (amendment) | Absci Corp | 0001628280-21-014101 ↗ |
| 2021-07-21 | EFFECT | EFFECT (declared effective) | Absci Corp | 9999999995-21-002868 ↗ |
| 2021-07-23 | 424B4 | 424B4 (final prospectus) | Absci Corp | 0001628280-21-014341 ↗ |
| 2022-09-02 | EFFECT | EFFECT (declared effective) | Absci Corp | 9999999995-22-002581 ↗ |
Prospectus pages read 2
| Filed | Form | Read as | Range | Price | Shares | Proceeds | Listing | Underwriters | What was found | Document |
|---|---|---|---|---|---|---|---|---|---|---|
| 2021-07-20 | S-1/A | registration statement | $15.00–$17.00 | 12,500,000 | - | Nasdaq ABSI | 5 | primary document; range, shares headline, cover names 5 | document ↗ | |
| 2021-07-23 | 424B4 | final prospectus | $16.00 | 12,500,000 | $200,000,000 | Nasdaq ABSI | 5 | primary document; price sentence, shares headline, proceeds table, cover names 5 | document ↗ |
Officers, directors and large holders Forms 3, 4 and 5
| Insider | Role | Title | Filings | Years | On this site |
|---|---|---|---|---|---|
| Bedrick Todd | Officer | See Remarks; SVP, CAO; SVP, Chief Accounting Officer; VP, CCPAO | 17 | 2021–2026 | |
| Casdin Capital, LLC | Director; Director,TenPercentOwner | 2 | 2021 | ||
| Casdin Eli | Director; Director,TenPercentOwner | 3 | 2021–2022 | ||
| Casdin Partners GP, LLC | Director; Director,TenPercentOwner | 2 | 2021 | ||
| Casdin Partners Master Fund, L.P. | Director; Director,TenPercentOwner | 2 | 2021 | ||
| CASDIN PRIVATE GROWTH EQUITY FUND GP, LLC | Director; Director,TenPercentOwner | 2 | 2021 | ||
| Casdin Private Growth Equity Fund, L.P. | Director; Director,TenPercentOwner | 2 | 2021 | ||
| Goel Nikhil | Officer | Chief Business Officer | 1 | 2021 | |
| Green Jeremy | Director; Director,TenPercentOwner | 6 | 2021–2024 | ||
| Jonasson Zachariah | Director; Director,Officer; Officer | CFO / CBO | 24 | 2021–2026 | |
| Korman Sarah | Officer | Chief Legal Officer; General Counsel | 7 | 2021–2023 | |
| Magovcevic-Liebisch Ivana | Director | 2 | 2021–2022 | ||
| McClain Sean | Director,Officer; Director,Officer,TenPercentOwner | Chief Executive Officer; President and Chief Executive; See Remarks | 18 | 2021–2026 | |
| MCGINNIS KAREN K | Director | 7 | 2021–2026 | ||
| Nagpal Amrit | Director | 4 | 2021–2024 | ||
| Phoenix General Partner II LLC | TenPercentOwner | 5 | 2021–2024 | ||
| Phoenix Venture Partners II LP | TenPercentOwner | 5 | 2021–2024 | ||
| Pihl Andreas | Officer | Chief Operating Officer | 2 | 2021 | |
| Redmile Biopharma Investments II, L.P. | Director,TenPercentOwner | 1 | 2021 | ||
| Redmile Group, LLC | Director; Director,TenPercentOwner | 6 | 2021–2024 | ||
| SCHIFFMAN GREGORY T | Officer | Chief Financial Officer | 4 | 2021–2023 | |
| Weinstock Matthew | Officer | Chief Technology Officer | 2 | 2021–2022 | |
| Sirosh Joseph | Director | 8 | 2022–2026 | ||
| Busch Andreas | Director; Officer | Chief Innovation Officer | 15 | 2022–2026 | |
| Rabinovitsj Daniel A | Director | 6 | 2022–2026 | ||
| Houten Frans Van | Director | 6 | 2023–2026 | ||
| Pangalos Menelas N | Director | 9 | 2024–2026 | ||
| Walker Shelby J. | Officer | Chief Legal Officer | 5 | 2024–2026 | |
| Szela Mary T | Director | 5 | 2025–2026 | ||
| Somaratne Ransi Mudalinayake | Officer | CMO, Head of R&D | 2 | 2026 |
Everyone who filed an insider report for this company, from the SEC’s Insider Transactions Data Sets (2006 on). Person pages are matched by name and state only.
Private offerings before or after (Form D)
| First filed | Issuer | Industry | Offering | Sold | Investors | Filings |
|---|---|---|---|---|---|---|
| 2021-03-30 | AbSci Corp | Biotechnology | $125,000,000 | $125,000,000 | 24 | 1 |
| 2020-10-30 | AbSci Corp | Biotechnology | $69,999,976 | $69,999,976 | 14 | 3 |
| 2019-12-19 | AbSci, LLC | Biotechnology | $15,000,000 | $10,360,013 | 17 | 1 |
| 2018-06-08 | AbSci, LLC | Biotechnology | $15,000,000 | $12,000,000 | 31 | 1 |
| 2016-04-21 | AbSci, LLC | Biotechnology | $6,000,000 | $3,661,572 | 12 | 1 |
Data: SEC EDGAR. The quarterly full index (every S-1, S-1/A, F-1 and F-1/A since 1993, with the pricing prospectus, notice of effectiveness and withdrawal request of each registrant) and the company submissions data (SIC, state of incorporation, address, EIN, tickers, former names). Company details are what EDGAR holds today, not at the time of the filing.
Also on this site Fuzzy
| Record | Name as filed | Where | Dataset | Matched by |
|---|---|---|---|---|
| Plan sponsor | ABSCI CORPORATION | WA | Form 5500 (employee benefit plans) | EIN (EXACT) |
| Form D issuer | AbSci Corp | WA | Form D private offerings | CIK (EXACT) |
| Nonprofit | TOASTMASTERS INTERNATIONAL | WA | Nonprofits (IRS Form 990) | same street address and ZIP code, 18105 SE MILL PLAIN BLVD 98683 (FUZZY: a shared address, not proof of a shared organization) |
| SEC filer | Absci Corp | SEC filers (EDGAR) | CIK (EXACT) | |
| Business registration | ABSCI CORPORATION | State business registries | name and state | |
| Form 5500 plan sponsor | ABSCI CORPORATION | EIN (EXACT) | ||
| Lobbying client | ABSCI | Federal lobbying (LDA) | name and state |
Matched by an identifier (EIN, CIK, CRD), by name and state or city, or by street address; a shared name or address is not proof of the same person or organization. Every link says how it was made; how the cross-referencing works.
Others with the same interests
SIC industry Services-Commercial Physical & Biological Research, WA first:
- ROSETTA INPHARMATICS INC WA
- Cascadian Therapeutics, Inc. WA
- WEED, INC. AZ
- GLYCOTEX, INC. C3
- COMBICHEM INC CA
- AURORA BIOSCIENCES CORP CA
- SIGNAL PHARMACEUTICALS INC CA
- DELTAGEN INC CA
- MAXYGEN INC CA
- KOSAN BIOSCIENCES INC CA
In other datasets, the same topic (Medical research) in WA:
- Form D issuer: AbSci Corp (Form D private offerings)
- Nonprofit: ACCESS ABILITIES UNLIMITED (Nonprofits (IRS Form 990))
Interests: Services-Commercial Physical & Biological Research · Medical research